Web5 feb 2015 · We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807). … Webuse of the JCOG0807 trial clinical data. Furthermore, the JCOG0807 trial is registered at the University Hospital Medical Information Network Clinical Trials Registry under the …

Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus ...

http://www.jcog.jp/document/s_0807.pdf Web2 feb 2015 · We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807). Promising efficacy and safety were shown in JCOG0807, and we have commenced a Phase III trial in September 2014 to confirm the superiority of 2-weekly DCF to CF for patients … haitian romance

食道癌 JCOG8807 臨床試験サマリ OncoTribune

Web1 set 2024 · Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) Cancer Sci , 105 ( 2014 ) , pp. 1189 - 1195 CrossRef View in Scopus Google Scholar WebWe carried out a phase I/II trial of adding 2-weekly docetaxel to cisplatin plus fluorouracil (CF) therapy (2-weekly DCF regimen) in esophageal cancer patients to investigate its … Web20 gen 2015 · 183 Background: ETS and DpR have been recognized as favorable prognostic factors of metastatic colorectal cancer. However, the effect of tumor shrinkage on clinical outcomes has not yet been reported for metastatic esophageal cancer (mEC). The purpose of the present study is to determine the associations of ETS and DpR with … bulls sharptail street 1 orange